Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Triamcinolone
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Triamcinolone

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (940 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739)

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Aristocort; Volon.

Where it fits in the MeSH classification

Broader topics
Pregnadienes; Steroids, Fluorinated
Narrower topics
Triamcinolone Acetonide

Research landscape

PubMed indexes 10,530 records tagged with the MeSH heading “Triamcinolone” (counts retrieved 2026-10-31). 1,108 of them (10.5%) were published from 2020 onward, and the busiest period so far is through 1999 with 4,736 records.

Reviews account for 549 records (5.2%) and meta-analyses for 84. Randomized controlled trials number 1,071 (10.2%) as a share of all records on the topic. Randomized trials make up a comparatively large share of this literature, which means many treatment questions have been tested directly.

PubMed records by publication periodthrough 1999: 4,736 records; 2000-2009: 2,298 records; 2010-2019: 2,388 records; 2020 onward: 1,108 records4,736through 19992,2982000-20092,3882010-20191,1082020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19994,736
2000-20092,298
2010-20192,388
2020 onward1,108
Share of records by publication typeReviews: 5.2 percent; Meta-analyses: 0.8 percent; Randomized controlled trials: 10.2 percentReviews5.2% (549)Meta-analyses0.8% (84)Randomized controlled trials10.2% (1,071)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 10,530 PubMed records
TypeRecordsShare
Reviews5495.2%
Meta-analyses840.8%
Randomized controlled trials1,07110.2%

Method: PubMed query "Triamcinolone"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
A randomized controlled trial of endoscopic steroid injection for prophylaxis of esophageal stenoses after extensive endoscopic submucosal dissection
Takahashi H, Arimura Y, Okahara S, Kodaira J, Hokari K, Tsukagoshi H, et al.
2015Randomized controlled trial
Design not recorded in structured metadata
100cc by
PMID 25609176 · DOI · PMC4308850
Dissolving Candlelit Microneedle for Chronic Inflammatory Skin Diseases
Ohn J, Jang M, Kang BM, Yang H, Hong JT, Kim KH, et al.
2021Research article
Design not recorded in structured metadata
42cc by
PMID 34306973 · DOI · PMC8292898
Preclinical evaluation of thermoreversible triamcinolone acetonide hydrogels for drug delivery to the inner ear
Engleder E, Honeder C, Klobasa J, Wirth M, Arnoldner C, Gabor F
2014Research article
Design not recorded in structured metadata
35cc by
PMID 24907595 · DOI · PMC4088987
Diagnostic imaging findings and management of osteoarthritis in pigs with image-guided intra-articular injections
Schultz RH, Hawkins JF, Hermida JA
2025Research article
Design not recorded in structured metadata
2cc by
PMID 40873115 · DOI · PMC12528815

A randomized controlled trial of endoscopic steroid injection for prophylaxis of esophageal stenoses after extensive endoscopic submucosal dissection [1]

Randomized controlled trial Takahashi H, Arimura Y, Okahara S, Kodaira J, Hokari K, Tsukagoshi H, et al. · · 2015 · cited 100 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundEsophageal stenosis following endoscopic submucosal dissection (ESD) is a serious adverse event that makes subsequent management more difficult.
Closing excerpt
ConclusionsProphylactic endoscopic steroid injection appears to be a safe means of relieving the severity of esophageal stenoses following extensive ESD.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (284 words)

BackgroundEsophageal stenosis following endoscopic submucosal dissection (ESD) is a serious adverse event that makes subsequent management more difficult.MethodsThis parallel, randomized, controlled, open-label study was designed to examine whether local steroid injection is an effective prophylactic treatment for esophageal stenoses following extensive ESD. This single center trial was conducted at the Keiyukai Hospital, a tertiary care center for gastrointestinal disease in Japan [University Hospital Medical Network Clinical Trial Registry (UMIN-CTR) on 15 September 2011 (UMIN000006327)]. Thirty-two patients with mucosal defects involving ≥75% of the esophageal circumference were randomized to receive a single dose of triamcinolone acetonide injections (n = 16) or be treated conventionally (n = 16). The primary outcome was the frequency of stricture requiring endoscopic dilatation; the surrogate primary endpoint was the number of dilatation sessions needed. Secondary outcomes included adverse event rates, the minimum diameter of the stenotic area and the duration of the course of dilatation treatments.ResultsThe frequency of stricture was not significantly different between the groups because of insufficient statistical power, but the number of dilatation sessions required was significantly less in the steroid group (6.1 sessions [95% confidence interval, CI 2.8-9.4] versus 12.5 [95% CI 7.1-17.9] sessions in the control group; P = 0.04). The perforation rate was similar in both groups. The minimum diameter of stenotic lumens was significantly greater in the treatment group than controls (11.0 mm versus 7.1 mm, respectively; P = 0.01). The perforation rate was not significantly different between the groups (1.0% versus 0.5% in the treatment and control group, respectively). Steroid injection was effective in cases of mucosal defects encompassing the entire esophageal circumference.ConclusionsProphylactic endoscopic steroid injection appears to be a safe means of relieving the severity of esophageal stenoses following extensive ESD.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 25609176 · DOI · PMC4308850

Dissolving Candlelit Microneedle for Chronic Inflammatory Skin Diseases [2]

Research article Ohn J, Jang M, Kang BM, Yang H, Hong JT, Kim KH, et al. · · 2021 · cited 42 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Chronic inflammatory skin diseases (CISDs) negatively impact a large number of patients.
Closing excerpt
This Candlelit-DMN with the applicator arouses the interest of dermatologists, who prefer it to the current TAILI procedure.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (183 words)

Chronic inflammatory skin diseases (CISDs) negatively impact a large number of patients. Injection of triamcinolone acetonide (TA), an anti-inflammatory steroid drug, directly into the dermis of diseased skin using needle-syringe systems is a long-established procedure for treating recalcitrant lichenified lesions of CISDs, referred to as TA intralesional injection (TAILI). However, TAILI causes severe pain, causing patients to be stressed and reluctant to undergo treatment. Furthermore, the practitioner dependency on the amount and depth of the injected TA makes it difficult to predict the prognosis. Here, candle flame ("candlelit")-shaped TA-loaded dissolving microneedles (Candlelit-DMN) are designed and fabricated out of biocompatible and biodegradable molecules. Candlelit-DMN distributes TA evenly across human skin tissue. Conjoined with the applicator, Candlelit-DMN is efficiently inserted into human skin in a standardized manner, enabling TA to be delivered within the target layer. In an in vivo skin inflammation mouse model, Candlelit-DMN inserted with the applicator effectively alleviates inflammation by suppressing inflammatory cell infiltration and cytokine gene expression, to the same extent as TAILI. This Candlelit-DMN with the applicator arouses the interest of dermatologists, who prefer it to the current TAILI procedure.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34306973 · DOI · PMC8292898

Preclinical evaluation of thermoreversible triamcinolone acetonide hydrogels for drug delivery to the inner ear [3]

Research article Engleder E, Honeder C, Klobasa J, Wirth M, Arnoldner C, Gabor F · · 2014 · cited 35 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Intratympanic glucocorticoid therapy aims to reduce the side effects associated with systemic long-time therapy of inner ear diseases or traumata after cochlear implantation.
Closing excerpt
All in all, fine tuned rheological experiments and absorption studies emerged as useful tools for preclinical evaluation of intratympanally administered hydrogels.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (246 words)

Intratympanic glucocorticoid therapy aims to reduce the side effects associated with systemic long-time therapy of inner ear diseases or traumata after cochlear implantation. For that purpose, thermoreversible hydrogels being fluid at room temperature but solid at body temperature are known to be appropriate drug delivery systems. In this work, the two key parameters sol-gel transition time and temperature of Poloxamer 407 (POX 407) based hydrogels containing oto-compatible micronized triamcinolone acetonide (TAAc) were evaluated by rheological experiments varying the concentrations of the different compounds. A 20% POX 407 hydrogel in PBS containing 30% TAAc emerged as the most appropriate formulation. Oscillation-rotation-oscillation studies at two temperature levels were found to be an useful in-vitro test system for the hydrogel which revealed sufficient storage stability at 4 °C, injectability of the sol, solidification within 20s at body temperature and persistent stiffness indicating prolonged adhesion at the round window membrane. According to the in-vitro release studies using the Transwell™ system, absorption of the poor water soluble TAAc is partly due to the low amount of dissolved drug but predominantly due to micellar transport resulting in a cumulative release of 262.6±13.4 μg TAAc within one week followed by a sustained release of 193.1±8.3 μg TAAc within the next three weeks. Thus, the formation of POX 407 micelles is the basis not only for gel formation but also absorptivity of TAAc. All in all, fine tuned rheological experiments and absorption studies emerged as useful tools for preclinical evaluation of intratympanally administered hydrogels.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 24907595 · DOI · PMC4088987

Diagnostic imaging findings and management of osteoarthritis in pigs with image-guided intra-articular injections [4]

Research article Schultz RH, Hawkins JF, Hermida JA · · 2025 · cited 2 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
ObjectiveTo describe the clinical and diagnostic imaging findings of pet pigs with osteoarthritis and determine the efficacy of intra-articular (IA) injections in managing lameness.
Closing excerpt
Clinical relevanceThe use of IA corticosteroids to treat lameness due to osteoarthritis in pigs represents an effective therapy that reduces lameness.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (227 words)

ObjectiveTo describe the clinical and diagnostic imaging findings of pet pigs with osteoarthritis and determine the efficacy of intra-articular (IA) injections in managing lameness.Study designRetrospective observational study.AnimalsA total of 16 pet pigs diagnosed with osteoarthritis and treated with non-steroidal medications and IA injections.MethodsCases, diagnostic imaging, and clinical data were collected from the medical records of Purdue University. The owners were interviewed by telephone to collect follow-up data regarding the degree of lameness following joint treatment.ResultsA total of 13 of 16 pigs presented for lameness evaluation. A diagnosis of osteoarthritis was determined with computed tomography (CT) (n = 10) or digital radiography (n = 7). In all, 24 joints were treated with triamcinolone. Following injection, 13 of 16 (81%) pigs showed improvement in lameness, as measured by decreases in lameness scores assigned by the owner (p = .0183). The duration of the effect ranged from a few weeks to several months. Those with no or minimal improvement tended to have advanced osteoarthritis in joints other than those treated. There were no complications reported. The use of CT for injection guidance did not show a significant difference in outcomes over the use of radiographic guidance.ConclusionWith an accurate diagnosis, IA injections seemed to be a beneficial therapy for pet pigs.Clinical relevanceThe use of IA corticosteroids to treat lameness due to osteoarthritis in pigs represents an effective therapy that reduces lameness.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40873115 · DOI · PMC12528815

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature [5]
    Jones R, Rhee DJ · Curr Opin Ophthalmol · 2006 · cited 247 times (Europe PMC)
  • Research article Intraocular pressure elevation after intravitreal triamcinolone acetonide injection [6]
    Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA · Ophthalmology · 2005 · cited 215 times (Europe PMC)
  • Research article The use of corticosteroids to treat keloids: a review [7]
    Roques C, Téot L · Int J Low Extrem Wounds · 2008 · cited 115 times (Europe PMC)
  • Research article Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases [8]
    Jonas JB, Kreissig I, Degenring R · Prog Retin Eye Res · 2005 · cited 110 times (Europe PMC)
  • Research article Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee [9]
    Paik J, Duggan ST, Keam SJ · Drugs · 2019 · cited 102 times (Europe PMC)
  • Research article Triamcinolone acetonide in ocular therapeutics [10]
    Jermak CM, Dellacroce JT, Heffez J, Peyman GA · Surv Ophthalmol · 2007 · cited 100 times (Europe PMC)

References

  1. Takahashi H, Arimura Y, Okahara S, Kodaira J, Hokari K, Tsukagoshi H, et al.. A randomized controlled trial of endoscopic steroid injection for prophylaxis of esophageal stenoses after extensive endoscopic submucosal dissection. . 2015. PMID 25609176 · DOI · PMC4308850
  2. Ohn J, Jang M, Kang BM, Yang H, Hong JT, Kim KH, et al.. Dissolving Candlelit Microneedle for Chronic Inflammatory Skin Diseases. . 2021. PMID 34306973 · DOI · PMC8292898
  3. Engleder E, Honeder C, Klobasa J, Wirth M, Arnoldner C, Gabor F. Preclinical evaluation of thermoreversible triamcinolone acetonide hydrogels for drug delivery to the inner ear. . 2014. PMID 24907595 · DOI · PMC4088987
  4. Schultz RH, Hawkins JF, Hermida JA. Diagnostic imaging findings and management of osteoarthritis in pigs with image-guided intra-articular injections. . 2025. PMID 40873115 · DOI · PMC12528815
  5. Jones R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006. PMID 16552251 · DOI
  6. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005. PMID 15808249 · DOI
  7. Roques C, Téot L. The use of corticosteroids to treat keloids: a review. Int J Low Extrem Wounds. 2008. PMID 18611924 · DOI
  8. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res. 2005. PMID 16005407 · DOI
  9. Paik J, Duggan ST, Keam SJ. Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee. Drugs. 2019. PMID 30847805 · DOI · PMC6437125
  10. Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007. PMID 17719372 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • AldosteroneDrugs and Chemicals
  • AndrostenedioneDrugs and Chemicals
  • BeclomethasoneDrugs and Chemicals
  • BetamethasoneDrugs and Chemicals
  • BudesonideDrugs and Chemicals
  • CalcitriolDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

10,530
PubMed records on this heading
11%
published since 2020
549
review articles
1,071
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • AldosteroneDrugs and Chemicals
  • AndrostenedioneDrugs and Chemicals
  • BeclomethasoneDrugs and Chemicals
  • BetamethasoneDrugs and Chemicals
  • BudesonideDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support